Beaumont Financial Advisors LLC Sells 5,128 Shares of Pfizer Inc. (NYSE:PFE)

Beaumont Financial Advisors LLC trimmed its position in shares of Pfizer Inc. (NYSE:PFE) by 20.1% in the 4th quarter, Holdings Channel.com reports. The firm owned 20,403 shares of the biopharmaceutical company’s stock after selling 5,128 shares during the quarter. Beaumont Financial Advisors LLC’s holdings in Pfizer were worth $587,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Adage Capital Partners GP L.L.C. boosted its holdings in shares of Pfizer by 40.5% in the third quarter. Adage Capital Partners GP L.L.C. now owns 4,739,672 shares of the biopharmaceutical company’s stock worth $157,215,000 after acquiring an additional 1,365,295 shares during the period. LifePlan Financial LLC bought a new position in shares of Pfizer in the fourth quarter worth $255,000. Brookstone Capital Management boosted its holdings in shares of Pfizer by 88.5% in the third quarter. Brookstone Capital Management now owns 452,352 shares of the biopharmaceutical company’s stock worth $14,109,000 after acquiring an additional 212,369 shares during the period. ETF Store Inc. boosted its holdings in shares of Pfizer by 12.0% in the third quarter. ETF Store Inc. now owns 6,803 shares of the biopharmaceutical company’s stock worth $214,000 after acquiring an additional 727 shares during the period. Finally, KLCM Advisors Inc. boosted its holdings in shares of Pfizer by 75.0% in the fourth quarter. KLCM Advisors Inc. now owns 173,793 shares of the biopharmaceutical company’s stock worth $5,004,000 after acquiring an additional 74,487 shares during the period. 68.36% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a report on Monday, April 15th. TD Cowen downgraded Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective on the stock. in a research report on Thursday, January 4th. Guggenheim assumed coverage on Pfizer in a research report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective on the stock. Finally, Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Twelve analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $36.88.

Pfizer Trading Up 2.4 %

NYSE PFE opened at $25.99 on Friday. The stock’s 50-day simple moving average is $27.11 and its two-hundred day simple moving average is $28.68. Pfizer Inc. has a twelve month low of $25.23 and a twelve month high of $40.37. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. The company has a market capitalization of $147.17 billion, a price-to-earnings ratio of 72.19, a PEG ratio of 1.14 and a beta of 0.61.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, topping the consensus estimate of ($0.19) by $0.29. The firm had revenue of $14.25 billion for the quarter, compared to the consensus estimate of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The company’s quarterly revenue was down 41.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.14 earnings per share. Research analysts forecast that Pfizer Inc. will post 2.24 EPS for the current fiscal year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.